2025-09-15 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the data you provided, formatted as a concise report in English.

## Intuitive Surgical Inc (ISRG) Analysis

**Company Overview:** Intuitive Surgical is a pioneer in robotic-assisted surgery, developing and manufacturing the da Vinci surgical system.

### 1. Performance vs. S&P 500 (VOO)

*   **ISRG Cumulative Return:** 92.87%
*   **VOO Cumulative Return:** 104.48%
*   **Absolute Divergence:** -11.61%
*   **Divergence Range:** Max: 56.6, Min: -42.2, Current: -42.2
*   **Relative Divergence:** 0.0% (at the lowest end of its historical divergence range)

**Analysis:** ISRG has underperformed the S&P 500, with a significant divergence between the returns. The relative divergence indicates that ISRG is currently at the lower end of its historical performance relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 68.0%  | 56.5%  | 39.0%  | 0.0   | 43.6   |
| 2016-2018  | 77.0%  | 63.4%  | 59.0%  | 0.0   | 57.2   |
| 2017-2019  | 81.0%  | 63.4%  | 52.0%  | 0.3   | 70.6   |
| 2018-2020  | 47.0%  | 63.4%  | 28.0%  | 0.2   | 97.8   |
| 2019-2021  | 91.0%  | 63.0%  | 43.0%  | 0.2   | 128.8  |
| 2020-2022  | -3.0%  | 69.9%  | -6.0%  | 0.2   | 95.1   |
| 2021-2023  | -5.0%  | 72.9%  | -23.0% | 0.9   | 120.9  |
| 2022-2024  | 26.0%  | 72.9%  | 0.0%   | 0.9   | 187.1  |
| 2023-2025  | 14.0%  | 72.9%  | -43.0% | 0.7   | 161.2  |

**Analysis:**

*   **CAGR:** Fluctuating growth rates, with significant highs in the past but lower recent figures.
*   **MDD:** Consistently high Maximum Drawdown values suggest significant volatility.
*   **Alpha:** Recent years show negative alpha, indicating underperformance relative to its benchmark.
*   **Beta:** Beta values are generally low, suggesting less sensitivity to market movements, but have increased recently.
*   **Cap:** The company's market capitalization has shown substantial growth over time, although it has fluctuated in recent periods.

### 2. Recent Stock Price Action

*   **Current Price:** 449.68
*   **Previous Close:** 455.85
*   **Change:** -1.35
*   **5-Day Moving Average:** 458.61
*   **20-Day Moving Average:** 466.6475
*   **60-Day Moving Average:** 493.3862

**Analysis:** The stock price is currently below all three moving averages, indicating a short-term downtrend. The recent price decrease compared to the previous close suggests continued negative momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 38.27 (Approaching oversold territory)
*   **PPO:** -0.0411
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (4 shares - Safe - MRI:0.33)
*   **Recent Relative Divergence Change (20-day):** -4.4 (Negative Trend)
*   **Expected Return:** 539.9% (Long-Term)

**Analysis:**

*   The MRI suggests a low-risk environment.
*   The RSI indicates that the stock is approaching oversold territory, which *could* signal a potential buying opportunity.
*   The negative PPO indicates bearish momentum.
*   The Hybrid Signal suggests a "Buy" signal, advising to use a large portion of available cash.
*   The negative change in relative divergence confirms short-term underperformance.
*   The high expected return suggests significant long-term potential (more than 2 years).
*   The price change of -1.35 indicates a recent downward pressure.

### 4. Recent News & Significant Events

*   **Positive:**
    *   Billionaire Phillipe Laffont's Coatue Management invested in ISRG.
    *   FDA-cleared features for da Vinci 5
    *   Software upgrades for da Vinci 5.
    *   Introduction of Real-Time Surgical Insights for da Vinci 5.
*   **Neutral/Cautious:**
    *   Jim Cramer's hesitation to "pull the trigger" on ISRG.

**Analysis:** Recent news is mixed. While new technological advancements and investment from a prominent investor are positive, caution from Jim Cramer could reflect near-term uncertainty.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price:** Average: 582.10, High: 685.00, Low: 350.00
*   **Recent Rating Changes:** No changes indicated in the provided data.

**Analysis:** The analyst consensus remains positive, with a "Buy" rating and a significant upside potential based on the average target price. However, the wide range between high and low target prices suggests some disagreement among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2024-07-19 | 1.48 | 2.01 B$   |
| 2025-07-23 | 1.48 | 2.01 B$   |

**Analysis:**

*   **EPS:** Fluctuating but generally increasing EPS over the past few quarters, with a recent dip.
*   **Revenue:** Consistent revenue growth, peaking in the most recent quarter.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |
| 2024-06-30   | $2.01B    | 68.30%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $17.85B   | 3.69%    |
| 2025-03-31   | $17.11B   | 4.08%    |
| 2024-12-31   | $16.43B   | 4.17%    |
| 2024-09-30   | $15.58B   | 3.63%    |
| 2024-06-30   | $14.71B   | 3.58%    |

**Analysis:**

*   **Revenue & Profitability:** Strong and growing revenue with consistently high profit margins.  Recent margin slightly decreased.
*   **Capital & Profitability:**  Equity is steadily increasing. ROE has fluctuated but remains at a healthy level.

### 7. Overall Summary

Intuitive Surgical (ISRG) presents a mixed picture. While the company exhibits strong fundamentals with increasing revenue, high profit margins, and positive long-term growth prospects reflected in its expected return, it is currently underperforming the S&P 500. Recent stock price action indicates a short-term downtrend, and the RSI suggests it's approaching oversold territory. Analyst consensus remains positive, and recent news includes significant technological advancements and institutional investment, but there's also some noted caution. The recent earnings data shows fluctuating EPS but strong revenue growth.

**Overall Recommendation:**

Based on this data, a cautious approach is warranted. The long-term potential seems promising, but the short-term indicators suggest potential further downside. Investors may want to consider averaging into a position over time, carefully monitoring future earnings reports, news flow, and technical indicators. A 90% cash buy strategy suggested could be reasonable.
